

**FOR IMMEDIATE RELEASE**

## **SANUWAVE Divests VersaTron<sup>®</sup> Veterinary Business**

**ALPHARETTA, Ga., June 3, 2009** – SANUWAVE, Inc. today announced the completion of its sale of the VersaTron veterinary business to Pulse Veterinary Technologies, LLC. The sale includes the VersaTron<sup>®</sup> family of products for the non-invasive management of musculoskeletal disorders causing chronic pain and lameness in veterinary patients, primarily horses and dogs.

Christopher M. Cashman, president and chief executive officer of SANUWAVE, commented, “This transaction allows SANUWAVE to continue to refine its focus within the human clinical markets, especially addressing the global advanced wound care sector. We are pleased PulseVet shares our excitement for this technology and a singular investment focus on developing veterinary market opportunities.” Cashman continued, “SANUWAVE has significant product opportunities in development for the advanced wound care and orthopedic market segments which we can now focus our efforts.”

SANUWAVE’s Investigational Device Exemption (IDE) clinical trial evaluating Pulse Acoustic Cellular Expression (PACE<sup>™</sup>) technology, utilizing the dermaPACE<sup>™</sup> device for the treatment of diabetic ulcers of the foot, has surpassed the two-thirds patient enrollment mark.

The dermaPACE device received European CE Mark approval in March 2007 for the treatment of acute and chronic defects of the skin and subcutaneous soft tissue e.g. post-operative wound healing defects, post traumatic wounds, deep partial thickness burns, decubitus ulcers, diabetic ulcers, and arterial ulcers. Early European results are very encouraging suggesting that PACE technology may offer an improved standard of care that may shorten a lengthy conservative therapy healing process and may make later operative measures, such as amputation, unnecessary. Given that current conservative therapy standard of care may not be effective for all patients, PACE may be a preferable, lower risk alternative. PACE has been reported to reduce wound size and increase the rate of wound closure in several peer reviewed publications.

### **About SANUWAVE, Inc.**

SANUWAVE, Inc. is a global medical technology company focused on the development and utilization of Extracorporeal Shock Wave Technology (ESWT) and Pulsed Acoustic Cellular Expression (PACE) for advanced wound care, orthopedic, cardiovascular and neurological conditions. Headquartered in Alpharetta, GA. SANUWAVE designs, manufactures, markets and services its industry leading products worldwide. The company’s dermaPACE has the European Community’s CE Mark approval for use in acute and chronic defects of the skin and subcutaneous soft tissue and is conducting an Investigational Device Exemption (IDE) clinical trial evaluating dermaPACE’s efficacy in the treatment of diabetic foot ulcers on the foot. SANUWAVE is undertaking extensive research into biological mechanisms and cellular effects of ESWT and PACE, to include anti-inflammatory response, angiogenesis promotion, and bactericidal capabilities. For more information, please visit [www.sanuwave.com](http://www.sanuwave.com).

## **About Pulse Veterinary Technologies, LLC**

Pulse Veterinary Technologies, LLC, located in Alpharetta, Ga., is a privately held company which develops and markets innovative, non-invasive therapies for the veterinary market. The company's principal technology is the VersaTron<sup>®</sup> family of products for the management of a variety of musculoskeletal disorders causing chronic pain and lameness. For more information, please visit [www.pulsevet.com](http://www.pulsevet.com).

Media Contact for SANUWAVE, Inc.  
Emily Davis  
770-419-7525  
Emily.davis@sanuwave.com

This press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements.